摘要
目的:评价莫西沙星注射液治疗老年中度社区获得性肺炎(CAP)的临床疗效及安全性。方法:采用前瞻性设计,将63例老年中度CAP患者随机分成治疗组31例和对照组32例,两组分别给予莫西沙星和加替沙星静脉治疗,观察细菌清除率、临床疗效、体温降至37.5℃时间、治疗4d后Fine积分变化、显著好转所需时间、住院天数及不良反应等各项指标。结果:两组有效率和细菌清除率差异无统计学意义(P>0.05),但治疗组体温降至37.5℃时间、治疗4 d后Fine积分变化、显著好转所需时间、住院天数等均明显好于对照组(P<0.05)。两组不良反应发生率无统计学差异(P>0.05)。结论:莫西沙星治疗老年中度社区获得性肺炎的临床疗效确切,安全性高。
Objective： To evaluate the clinical efficacy of moxifloxacin in the treatment of elderly patients with moderate community acquired pneumonia（CAP）. Method： A total of 63 patients were randomly divided into the treatment group（ n = 31 ） treated by moxifloxacin and controlled group （n = 32 ）treated by gatifloxacin. The effective rate, bacterial clearance rate, time of defervescence to 37.5 ℃, fine score at day 4, time of obvious improvement, hospitalization stay and adverse effects were observed. Result： The difference of the effective rate and bacterial clearance rate between the two groups had no statistically difference, The difference of the time of defervescence to 37.5 ℃, fine score at day 4, the time of obvious improvement and hospitalization stay between them had some statistical difference. There was no statistical difference in adverse effects. Conclusion： Moxifloxacin is effective and safe in the treatment of moderate community acquired pneumonia（CAP） in elderly patients.
出处
《药物流行病学杂志》
CAS
2007年第4期207-209,共3页
Chinese Journal of Pharmacoepidemiology
关键词
莫西沙星
加替沙星
肺炎
社区获得性
Moxifloxacin
Gatifloxacin
Community acquired pneumonia（CAP）
